Literature DB >> 15361952

[Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina].

Mirtha L Streiger1, Mónica L del Barco, Diana L Fabbro, Enrique D Arias, Norberto A Amicone.   

Abstract

Clinical and epidemiological results of 95 treated and untreated chronic chagasic children, with an up to 24 years follow-up period are presented. This population studied in the 1/14 age bracket, residing in Santa Fe city, Argentina, was diagnosed through Chagas-specific conventional serologic reactions. Clinical examination was supplemented with electrocardiogram, chest X-rays, and blood and urine tests for evaluating hepatic function. The drugs employed were nifurtimox or benznidazole. In post treatment period xenodiagnosis was made in 33 patients. Regarding Trypanosoma cruzi transmission, the studied individuals presented multi-risk antecedents: vectorial, congenital and/or blood transfusion. Among 24 untreated children 14 were controlled during 8/24 years: all this patients maintained the initial antibody concentration and clinical status. From 71 treated patients 49 were followed-up 4/24 years: 14 remained positive, 6 presented dubious results, and 29 showed final non-reactive results. 9 of this presented sometimes oscilating results. In 1/6 age bracket children, the serology turned negative after 3.5 years (median) once the treatment was finished, while patients treated in the 7/14 age bracket, the median of negativization was 8 years. 3.8% did not tolerate the drug. None of the groups changed their clinical condition. The untreated children did not change the serology. The percentage of treated children presenting negative serological results decrease according to the age when treatment was given: 75% became negative when treated at < or =4 years old and 43% when treated at > or =9 years old.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361952     DOI: 10.1590/s0037-86822004000500001

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  18 in total

1.  Two approaches to discovering and developing new drugs for Chagas disease.

Authors:  J H McKerrow; P S Doyle; J C Engel; L M Podust; S A Robertson; R Ferreira; T Saxton; M Arkin; I D Kerr; L S Brinen; C S Craik
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

Review 2.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

Authors:  Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt
Journal:  Cochrane Database Syst Rev       Date:  2014-05-27

3.  Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole.

Authors:  María Elena Marson; Jaime Altcheh; Guillermo Moscatelli; Samanta Moroni; Facundo García-Bournissen; Guido Enrique Mastrantonio
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-08       Impact factor: 2.441

Review 4.  Trypanosoma cruzi and Chagas' Disease in the United States.

Authors:  Caryn Bern; Sonia Kjos; Michael J Yabsley; Susan P Montgomery
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

Review 5.  Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.

Authors:  Facundo Garcia-Bournissen; Jaime Altcheh; Norberto Giglio; Guido Mastrantonio; Carlos Omar Della Védova; Gideon Koren
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

6.  Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease.

Authors:  Olga Sánchez Negrette; Fernando J Sánchez Valdéz; Carlos D Lacunza; María Fernanda García Bustos; María Celia Mora; Alejandro D Uncos; Miguel Angel Basombrío
Journal:  Clin Vaccine Immunol       Date:  2007-12-05

7.  Therapy of chagas disease: implications for levels of prevention.

Authors:  Sergio Sosa-Estani; Lisandro Colantonio; Elsa Leonor Segura
Journal:  J Trop Med       Date:  2012-03-05

Review 8.  Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.

Authors:  Yanina Sguassero; Cristina B Cuesta; Karen N Roberts; Elizabeth Hicks; Daniel Comandé; Agustín Ciapponi; Sergio Sosa-Estani
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

9.  Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.

Authors:  Oliver Yun; M Angeles Lima; Tom Ellman; Wilma Chambi; Sandra Castillo; Laurence Flevaud; Paul Roddy; Fernando Parreño; Pedro Albajar Viñas; Pedro Pablo Palma
Journal:  PLoS Negl Trop Dis       Date:  2009-07-07

10.  Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.

Authors:  Clara Crespillo-Andújar; Emmanuele Venanzi-Rullo; Rogelio López-Vélez; Begoña Monge-Maillo; Francesca Norman; Ana López-Polín; José A Pérez-Molina
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.